Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 73.1% and 54.4% per annum respectively. EPS is expected to grow by 72.6% per annum. Return on equity is forecast to be -87.9% in 3 years.

Key information

73.1%

Earnings growth rate

72.6%

EPS growth rate

Biotechs earnings growth	37.1%
Revenue growth rate	54.4%
Future return on equity	-87.9%
Analyst coverage	Good
Last updated	26 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0JXI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	996	126	99	382	13
12/31/2025	574	-288	-226	-195	16
12/31/2024	168	-502	-530	-428	13
9/30/2024	77	-519	-438	-431	N/A
6/30/2024	15	-510	-456	-449	N/A
3/31/2024	N/A	-444	-391	-389	N/A
12/31/2023	N/A	-374	-326	-324	N/A
9/30/2023	N/A	-347	-303	-303	N/A
6/30/2023	N/A	-330	-277	-277	N/A
3/31/2023	N/A	-315	-259	-259	N/A
12/31/2022	N/A	-295	-225	-225	N/A
9/30/2022	N/A	-274	-215	-214	N/A
6/30/2022	N/A	-256	-201	-201	N/A
3/31/2022	N/A	-247	-191	-190	N/A
12/31/2021	N/A	-242	-184	-184	N/A
9/30/2021	N/A	-236	-191	-191	N/A
6/30/2021	N/A	-231	-193	-193	N/A
3/31/2021	N/A	-219	-171	-170	N/A
12/31/2020	N/A	-202	-158	-158	N/A
9/30/2020	N/A	-171	-115	-115	N/A
6/30/2020	N/A	-134	-79	-78	N/A
3/31/2020	N/A	-105	-66	-66	N/A
12/31/2019	N/A	-84	-42	-42	N/A
9/30/2019	N/A	-68	-36	-36	N/A
6/30/2019	N/A	-55	-30	-30	N/A
3/31/2019	N/A	-42	-23	-23	N/A
12/31/2018	N/A	-33	-26	-26	N/A
9/30/2018	N/A	-30	-25	-25	N/A
6/30/2018	N/A	-30	N/A	-25	N/A
3/31/2018	N/A	-32	N/A	-27	N/A
12/31/2017	N/A	-31	N/A	-22	N/A
9/30/2017	N/A	-30	N/A	-22	N/A
6/30/2017	N/A	-36	N/A	-26	N/A
3/31/2017	N/A	-31	N/A	-21	N/A
12/31/2016	N/A	-26	N/A	-18	N/A
9/30/2016	N/A	-21	N/A	-13	N/A
6/30/2016	N/A	-8	N/A	-5	N/A
3/31/2016	N/A	-7	N/A	-3	N/A
12/31/2015	N/A	-7	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0JXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: 0JXI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0JXI is expected to become profitable in the next 3 years.

Revenue vs Market: 0JXI's revenue (54.4% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0JXI's revenue (54.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0JXI is forecast to be unprofitable in 3 years.

Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2026

No longer forecast to breakeven

Forecast breakeven date moved forward to 2025

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

Recent updates

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Forecast to breakeven in 2026

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Forecast breakeven date moved forward to 2025

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Forecast breakeven date pushed back to 2026

New major risk - Financial position

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

New major risk - Share price stability

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Insufficient new directors

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Insufficient new directors

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies